Stockscreener 앱 받기
3.14
0.63%
-0.02
전일 마감가:
$3.16
열려 있는:
$3.17
하루 거래량:
339.36K
Relative Volume:
1.19
시가총액:
$82.53M
수익:
$247.99M
순이익/손실:
$-521.97M
주가수익비율:
-4.3611
EPS:
-0.72
순현금흐름:
$-194.28M
1주 성능:
-0.32%
1개월 성능:
-32.76%
6개월 성능:
-69.40%
1년 성능:
-82.73%
1일 변동 폭
$3.11
$3.39
1주일 범위
$2.97
$3.46
52주 변동 폭
$2.655
$20.40
23 Andme Holding Co Stock (ME) Company Profile
명칭
23 Andme Holding Co
전화
(650) 938-6300
주소
223 N. MATHILDA AVE., SUNNYVALE
ME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ME
23 Andme Holding Co
|
3.14 | 82.53M | 247.99M | -521.97M | -194.28M | -0.72 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
23 Andme Holding Co Stock (ME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-29 | 개시 | Berenberg | Buy |
| 2022-09-22 | 개시 | Cowen | Outperform |
| 2021-11-15 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-08-17 | 개시 | Credit Suisse | Outperform |
| 2021-07-12 | 개시 | Citigroup | Buy |
23 Andme Holding Co 주식(ME)의 최신 뉴스
23andMe’s stock falls after company says there’s substantial doubt it can stay in business - MSN
23andMe shares dip as Q2 loss widens despite revenue beat By Investing.com - Investing.com Nigeria
Do Redditors Think That 23andMe Holding Co. (ME) Has a Big Upside Potential? - Insider Monkey
Struggling 23andMe Is Exploring Splitting the DNA Company in Two - MSN
23andMe inks research deal with Mirador Therapeutics By Investing.com - Investing.com Canada
23andMe to slash 40% of its workforce, end therapeutics program to cut costs - MSN
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation - The Manila Times
23andMe inks research deal with Mirador Therapeutics - Investing.com India
23andMe and Mirador Therapeutics Enter Into Strategic - GlobeNewswire
23andMe Partners with Mirador in Major Drug Development Collaboration | ME Stock News - StockTitan
Earnings call: 23andMe announces restructuring and focus shift By Investing.com - Investing.com Australia
Earnings call: 23andMe announces restructuring and focus shift - Investing.com
23andMe Holding Co. (NASDAQ:ME) Q2 2025 Earnings Call Transcript - Insider Monkey
23andMe Reports Improved Financial Metrics Amid Revenue Decline - TipRanks
23Andme Holding Co earnings missed by $2.16, revenue topped estimates - Investing.com Canada
23andMe cuts 40% of its workforce - Fox Business
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs - Yahoo Finance
23andMe’s stock turns lower after company posts its latest quarterly loss - MSN
23andMe cuts 40% of its workforce, discontinues all therapy programs - Reuters
23andMe to Explore Strategic Alternatives - Marketscreener.com
23andMe Holding Co Reports Q2 FY25 Revenue of $44 Million, Missi - GuruFocus.com
23andMe Holding Co. (ME) Misses Q2 EPS by 216c - StreetInsider.com
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results - GlobeNewswire
23andMe Holding Co. Announces Reduce Overall Headcount - Marketscreener.com
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future - The Manila Times
23andMe Announces Business Restructuring to Streamline - GlobeNewswire
23andMe Cuts 40% of Workforce, Exits Therapeutics in Major Cost-Saving Overhaul | ME Stock News - StockTitan
Earnings Outlook For 23andMe Holding - Benzinga
Federal law could prevent your 23andMe data deletion, but you should still try - Android Police
CORRECTION23andMe to Report Q2 FY2025 Financial Results - The Manila Times
23andMe Revises Q2 FY2025 Earnings Release Time to Pre-Market on Nov 12 | ME Stock News - StockTitan
23andMe to Report Q2 FY2025 Financial Results - The Manila Times
23andMe Sets Q2 FY2025 Earnings Call for November 12: What Investors Need to Know | ME Stock News - StockTitan
Vanguard Group's Strategic Acquisition of 23andMe Shares - GuruFocus.com
DNA-testing site 23andMe fights for survival - BBC.com
23andMe turns to CFOs to fill director roles after mass board exit - Yahoo Finance
23andMe regains Nasdaq compliance, avoids delisting By Investing.com - Investing.com Australia
23andMe regains Nasdaq compliance, avoids delisting - Investing.com
23andMe Regains Nasdaq Compliance and Ensures Listing - TipRanks
23andMe Regains Compliance With Nasdaq Listing Requirements - The Manila Times
23andMe Stock Price Prediction: 2024, 2025, 2030 - Benzinga
23andMe Holding Expands Board with New Appointments - TipRanks
23andMe expands board with three new directors - Investing.com
23andMe Appoints Three New Independent Directors to Board - The Manila Times
23andMe expands board with three new directors By Investing.com - Investing.com UK
23 Andme Holding Co (ME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.41%
자본화:
|
볼륨(24시간):